Xenetic Biosciences Q2 2025 Earnings Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress CEVA Q1 2026 Earnings EPS Surprises by 122 Amid Strong Licensing Momentum SU Q1 2026 Earnings Strong EPS Beat Reflects Operational Discipline AIT Q1 2026 Earnings Narrow Profit Miss Amidst Steady Operational Performance REZI Q1 2026 Earnings EPS Beats Estimates Stock Gains 4 AR Q1 2026 Earnings EPS Falls Just Short of Expectations Stock Declines